statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial...

Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and...

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor...

Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering PR Newswire CRANFORD, N.J., April...

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering Citius Pharmaceuticals Announces $15 Million Registered Direct Offering PR Newswire CRANFORD, N.J., April 26, 2024 CRANFORD...

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma Citius Pharmaceuticals Announces Addition of...

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference PR Newswire CRANFORD...

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma Citius...

Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program PR...

Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration...

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Watchers	22,133
52-Wk Low	$0.60
52-Wk High	$1.40

Volume	1.82M
52-Wk High	$1.40
52-Wk Low	$0.60

Period	Estimated	Reported	Surprise	Result
Q3'24	-$0.06	--	--	N/A
Q2'24	-$0.06	-$0.05	9.09%	BEAT
Q1'24	$0.13	-$0.06	-146.15%	MISSED
Q4'23	-$0.02	-$0.07	-250.00%	MISSED
Q3'23	-$0.06	-$0.06	--	EXPECTED

CTXR Citius Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals